Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

Wenfeng Fang; Yunpeng Yang; Yuxiang Ma; Shaodong Hong; Lizhu Lin; Xiaohui He; Jianping Xiong; Ping Li; Hongyun Zhao; Yan Huang; Yang Zhang; Likun Chen; Ningning Zhou; Yuanyuan Zhao; Xue Hou; Qing Yang; Li Zhang

doi:10.1016/s1470-2045(18)30495-9

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

Wenfeng Fang(Sun Yat-sen University), Yunpeng Yang(Sun Yat-sen University), Yuxiang Ma(Sun Yat-sen University), Shaodong Hong(Sun Yat-sen University Cancer Center), Lizhu Lin(First Affiliated Hospital of Guangzhou University of Chinese Medicine), Xiaohui He(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianping Xiong(Nanchang University), Ping Li(West China Hospital of Sichuan University), Hongyun Zhao(Sun Yat-sen University Cancer Center), Yan Huang(Sun Yat-sen University), Yang Zhang(Sun Yat-sen University Cancer Center), Likun Chen(Sun Yat-sen University), Ningning Zhou(Sun Yat-sen University Cancer Center), Yuanyuan Zhao(Sun Yat-sen University), Xue Hou(Sun Yat-sen University), Qing Yang(Jiangsu Hengrui Medicine (China)), Li Zhang(Sun Yat-sen University)

The Lancet Oncology

September 10, 2018

10.1016/s1470-2045(18)30495-9

Cited by 505

Abstract

Related Papers

No related papers found

Powered by citation graph analysis